Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients

被引：0
|
作者：
Nishimura, Meiko
Kogawa, Takahiro
Akaishi, Yuko
Ogata, Misato
Masuda, Jun
Terada, Mitsuo
Sakai, Hitomi
Nozawa, Kazuki
Kurozumi, Sasagu
Yokoe, Takamichi
Ozaki, Yukinori Ozaki
Yazaki, Shu
Onishi, Mai
Iwasa, Tsutomu
Onoe, Takuma
Okumura, Yuta
Nakayama, Sayaka
Hagio, Kanako
Takahashi, Yuko
Tanino, Hirokazu
Tsurutani, Junji
Matsumoto, Koji
Shimokawa, Mototsugu
Takano, Toshimi
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-19-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-19-02
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [22] The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer
    Oikawa, Masahiro
    Ishida, Mayumi
    Nakamura, Yoshiaki
    Nishimura, Sumiko
    Koga, Chinami
    Saruwatari, Akihiro
    Igawa, Akiko
    Akiyoshi, Sayuri
    Koi, Yumiko
    Ohno, Shinji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
  • [24] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266
  • [25] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [26] Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
    Pascual, Javier
    Gil-Gil, Miguel
    Proszek, Paula
    Zielinski, Christoph
    Reay, Alistair
    Ruiz-Borrego, Manuel
    Cutts, Rosalind
    Ciruelos Gil, Eva M.
    Feber, Andrew
    Munoz-Mateu, Montserrat
    Swift, Claire
    Bermejo, Begona
    Herranz, Jesus
    Margeli Vila, Mireia
    Anton, Antonio
    Kahan, Zsuzsanna
    Csoeszi, Tibor
    Liu, Yuan
    Fernandez-Garcia, Daniel
    Garcia-Murillas, Isaac
    Hubank, Michael
    Turner, Nicholas C.
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4166 - 4177
  • [27] Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
    Hohmann, L.
    Sigurjonsdottir, K.
    Bosch, A.
    Nacer, D. F.
    Veerla, S.
    Hakkinen, J.
    Vallon-Christersson, J.
    Borg, A.
    Memari, Y.
    Davies, H.
    Nik-Zainal, S.
    Staaf, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S310 - S311
  • [28] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675
  • [30] Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib.
    Tamragouri, Keerthi
    Cobleigh, Melody A.
    Rao, Ruta D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345